NPH INSULIN

Nph Insulin Adverse Events Reported to the FDA Over Time

How are Nph Insulin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nph Insulin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nph Insulin is flagged as the suspect drug causing the adverse event.

Most Common Nph Insulin Adverse Events Reported to the FDA

What are the most common Nph Insulin adverse events reported to the FDA?

Hypoglycaemia	76 (9.18%)
Blood Glucose Increased	34 (4.11%)
Blood Glucose Decreased	32 (3.86%)
Loss Of Consciousness	20 (2.42%)
Renal Failure Acute	16 (1.93%)
Confusional State	13 (1.57%)
Glycosylated Haemoglobin Increased	13 (1.57%)
Mental Status Changes	13 (1.57%)
Pneumonia	13 (1.57%)
Hyperhidrosis	12 (1.45%)
Acute Respiratory Failure	10 (1.21%)
	Show More
Coma	10 (1.21%)
Pancreatitis Acute	10 (1.21%)
Blood Urea Increased	9 (1.09%)
Nausea	9 (1.09%)
Blood Cholesterol Increased	8 (.97%)
Dehydration	8 (.97%)
Dyspnoea	8 (.97%)
Fall	8 (.97%)
Syncope	8 (.97%)
Asthenia	7 (.85%)
Blood Triglycerides Increased	7 (.85%)
Dizziness	7 (.85%)
Feeling Abnormal	7 (.85%)
Medication Error	7 (.85%)
Tremor	7 (.85%)
Depressed Level Of Consciousness	6 (.72%)
Diabetes Mellitus	6 (.72%)
Diabetes Mellitus Inadequate Contro...	6 (.72%)
Hypertension	6 (.72%)
Pancreatitis	6 (.72%)
Renal Failure	6 (.72%)
Treatment Noncompliance	6 (.72%)
Cardiac Arrest	5 (.6%)
Cardiac Failure Congestive	5 (.6%)
Diabetic Ketoacidosis	5 (.6%)
Drug Dose Omission	5 (.6%)
Microalbuminuria	5 (.6%)
Acute Prerenal Failure	4 (.48%)
Aortic Disorder	4 (.48%)
Aortic Valve Stenosis	4 (.48%)
Blood Creatinine Increased	4 (.48%)
Creatinine Renal Clearance Decrease...	4 (.48%)
Drug Ineffective	4 (.48%)
Hyperglycaemia	4 (.48%)
Incorrect Dose Administered	4 (.48%)
Left Ventricular Hypertrophy	4 (.48%)
Mitral Valve Incompetence	4 (.48%)
Myocardial Ischaemia	4 (.48%)
Unresponsive To Stimuli	4 (.48%)
Vomiting	4 (.48%)
Anorexia	3 (.36%)
Back Pain	3 (.36%)
Blood Pressure Diastolic Increased	3 (.36%)
Blood Pressure Increased	3 (.36%)
Cardio-respiratory Arrest	3 (.36%)
Cardiogenic Shock	3 (.36%)
Completed Suicide	3 (.36%)
Diarrhoea	3 (.36%)
Drug Administration Error	3 (.36%)
Dyslipidaemia	3 (.36%)
General Physical Health Deteriorati...	3 (.36%)
Haemothorax	3 (.36%)
Hepatic Function Abnormal	3 (.36%)
Hyperkalaemia	3 (.36%)
Hypoglycaemic Encephalopathy	3 (.36%)
Hypophagia	3 (.36%)
Impaired Gastric Emptying	3 (.36%)
Lethargy	3 (.36%)
Malaise	3 (.36%)
Multiple Fractures	3 (.36%)
Multiple Injuries	3 (.36%)
Obesity	3 (.36%)
Oedema Peripheral	3 (.36%)
Orthostatic Hypotension	3 (.36%)
Polydipsia	3 (.36%)
Polyuria	3 (.36%)
Proteinuria	3 (.36%)
Respiratory Arrest	3 (.36%)
Retroperitoneal Neoplasm	3 (.36%)
Somnolence	3 (.36%)
Agitation	2 (.24%)
Agonal Death Struggle	2 (.24%)
Anaemia	2 (.24%)
Anaphylactic Reaction	2 (.24%)
Angina Pectoris	2 (.24%)
Anxiety	2 (.24%)
Blindness	2 (.24%)
Blood Creatine Phosphokinase Increa...	2 (.24%)
Blood Glucose Abnormal	2 (.24%)
Blood Glucose Fluctuation	2 (.24%)
Blood Potassium Increased	2 (.24%)
Blood Pressure Systolic Increased	2 (.24%)
Blood Uric Acid Increased	2 (.24%)
Body Mass Index Increased	2 (.24%)
Bradycardia	2 (.24%)
Brain Natriuretic Peptide Increased	2 (.24%)
C-reactive Protein Increased	2 (.24%)
Cardiac Disorder	2 (.24%)
Chest Pain	2 (.24%)
Cold Sweat	2 (.24%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Nph Insulin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nph Insulin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nph Insulin

What are the most common Nph Insulin adverse events reported to the FDA?

Glucose Metabolism Disorders	95 (11.47%)
Metabolic, Nutritional And Blood Ga...	90 (10.87%)
Neurological	73 (8.82%)
Renal Disorders	27 (3.26%)
Medication Errors	26 (3.14%)
Renal And Urinary Tract Investigati...	22 (2.66%)
Respiratory	22 (2.66%)
Infections - Pathogen Unspecified	21 (2.54%)
Lipid Analyses	21 (2.54%)
Cardiac Arrhythmias	17 (2.05%)
Electrolyte And Fluid Balance Condi...	16 (1.93%)
	Show More
Exocrine Pancreas Conditions	16 (1.93%)
Injuries	16 (1.93%)
Cardiac And Vascular Investigations	15 (1.81%)
Skin Appendage Conditions	14 (1.69%)
Urinary Tract Signs	14 (1.69%)
Deliria	13 (1.57%)
Gastrointestinal Signs	13 (1.57%)
Psychiatric	13 (1.57%)
Appetite And General Nutritional	12 (1.45%)
Coronary Artery	10 (1.21%)
Cardiac Valve	9 (1.09%)
Administration Site Reactions	8 (.97%)
Heart Failures	8 (.97%)
Lifestyle Issues	8 (.97%)
Anxiety Disorders	7 (.85%)
Movement Disorders	7 (.85%)
Myocardial	7 (.85%)
Allergic Conditions	6 (.72%)
Gastrointestinal Motility And Defec...	6 (.72%)
Peripheral Neuropathies	6 (.72%)
Therapeutic And Nontherapeutic Effe...	6 (.72%)
Vascular Hypertensive	6 (.72%)
Diabetic Complications	5 (.6%)
Epidermal And Dermal Conditions	5 (.6%)
Musculoskeletal And Connective Tiss...	5 (.6%)
Physical Examination Topics	5 (.6%)
Vision	5 (.6%)
Water, Electrolyte And Mineral	5 (.6%)
Anemias Nonhemolytic And Marrow Dep...	4 (.48%)
Bone And Joint Injuries	4 (.48%)
Decreased And Nonspecific Blood Pre...	4 (.48%)
Hematology Investigations	4 (.48%)
Pleural	4 (.48%)
Vascular	4 (.48%)
Bacterial Infectious	3 (.36%)
Cardiac Disorder Signs	3 (.36%)
Chemical Injury And Poisoning	3 (.36%)
Encephalopathies	3 (.36%)
Enzyme	3 (.36%)
Gastrointestinal Neoplasms Malignan...	3 (.36%)
Hepatic And Hepatobiliary	3 (.36%)
Hepatobiliary	3 (.36%)
Lipid Metabolism	3 (.36%)
Lower Respiratory Tract Disorders	3 (.36%)
Mental Impairment	3 (.36%)
Protein And Chemistry Analyses	3 (.36%)
Seizures	3 (.36%)
Sleep Disorders	3 (.36%)
Suicidal And Self-injurious Behavio...	3 (.36%)
Bone And Joint Therapeutic Procedur...	2 (.24%)
Fatal Outcomes	2 (.24%)
Fungal Infectious	2 (.24%)
Muscle	2 (.24%)
Musculoskeletal And Connective Tiss...	2 (.24%)
Neonatal And Perinatal Conditions	2 (.24%)
Platelet	2 (.24%)
Retina, Choroid And Vitreous Hemorr...	2 (.24%)
Therapeutic Procedures And Supporti...	2 (.24%)
Upper Respiratory Tract Disorders	2 (.24%)
Abdominal Hernias And Other Abdomin...	1 (.12%)
Acid-base	1 (.12%)
Arteriosclerosis, Stenosis, Vascula...	1 (.12%)
Changes In Physical Activity	1 (.12%)
Connective Tissue Disorders	1 (.12%)
Cranial Nerve Disorders	1 (.12%)
Depressed Mood Disorders	1 (.12%)
Endocrine Investigations	1 (.12%)
Eye	1 (.12%)
Gastrointestinal Hemorrhages	1 (.12%)
Gastrointestinal Inflammatory Condi...	1 (.12%)
Gastrointestinal Tract Disorders Co...	1 (.12%)
Gastrointestinal Vascular Condition...	1 (.12%)
Hepatobiliary Therapeutic Procedure...	1 (.12%)
Joint	1 (.12%)
Metabolism	1 (.12%)
Miscellaneous And Site Unspecified ...	1 (.12%)
Mood Disorders	1 (.12%)
Musculoskeletal And Connective Tiss...	1 (.12%)
Ocular Structural Change, Deposit A...	1 (.12%)
Reproductive Neoplasms Male Maligna...	1 (.12%)
Schizophrenia And Other Psychotic	1 (.12%)
Skin And Subcutaneous Tissue	1 (.12%)
Spinal Cord And Nerve Root	1 (.12%)
Tissue	1 (.12%)
Vascular Hemorrhagic	1 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nph Insulin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nph Insulin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.